Who are Vγ2Vδ2 T lymphocyte-based immunotherapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/v-2v-2-t-lymphocyte-based-immunotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Vγ2Vδ2 T lymphocyte-based immunotherapy — Competitive Intelligence Brief

Vγ2Vδ2 T lymphocyte-based immunotherapy (Vγ2Vδ2 T lymphocyte-based immunotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell-based immunotherapy. Area: Oncology.

marketed Cell-based immunotherapy Vγ2Vδ2 T cell receptor; phosphoantigens and stress-induced ligands Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Vγ2Vδ2 T lymphocyte-based immunotherapy (Vγ2Vδ2 T lymphocyte-based immunotherapy) — Shanghai Pulmonary Hospital, Shanghai, China. Vγ2Vδ2 T lymphocyte-based immunotherapy activates and expands a specialized subset of gamma-delta T cells to enhance anti-tumor immune responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vγ2Vδ2 T lymphocyte-based immunotherapy TARGET	Vγ2Vδ2 T lymphocyte-based immunotherapy	Shanghai Pulmonary Hospital, Shanghai, China	marketed	Cell-based immunotherapy	Vγ2Vδ2 T cell receptor; phosphoantigens and stress-induced ligands

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell-based immunotherapy class)

Shanghai Pulmonary Hospital, Shanghai, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vγ2Vδ2 T lymphocyte-based immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/v-2v-2-t-lymphocyte-based-immunotherapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab